Wednesday - February 25, 2026
Johnson & Johnson Seeks FDA Approval of Imaavy as the First-Ever FDA-Approved Treatment for Warm Autoimmune Hemolytic Anemia
February 25, 2026
RARITAN, New Jersey, Feb. 25 -- Johnson and Johnson Innovative Medicine issued the following news release on Feb. 24, 2026:

* * *

Johnson & Johnson seeks FDA approval of IMAAVY(R) (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)

Data from the pivotal ENERGY trial showed IMAAVY(R) produced a rapid and durable hemoglobin responsea in wAIHA

Currently no FDA-approved therapies are availabl . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products